Last reviewed · How we verify

NCT07070557

High Neutrophil-to-Lymphocyte Ratio and Patients With Hemodialysis

Not yet recruiting Last updated 17 July 2025
What this trial tests

trial testing neutrophil lymphocyte ratio and platelet lymphocyte ratio in Hemodialysis Patient in 100 participants. Not yet recruiting.

Timeline
15 July 2025
Primary endpoint
15 February 2026
1 May 2026

Quick facts

Lead sponsorSohag University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment100
Start date15 July 2025
Primary completion15 February 2026
Estimated completion1 May 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

18 Months and older, any sex, with Hemodialysis Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemodialysis Patient

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07070557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing